Safely and well invested

Values & Performance of HAEMATO AG

Have you invested in HAEMATO AG or are you interested in the company's performance as a capital market participant? Here you will find all the important information about us and our activities: Current financial reports, key figures and our financial calendar.

Directly to the share price

€ 238 mio. sales in 2020

635,000 packages sold annually

31 % sales CAGR since 2007

More than 7,000 customers

Investor News

HAEMATO AG (ISIN: DE000289VV1), has continued its growth course in the first months of 2021. Due to a strong core business, consolidated sales (IFRS) increased by 22% to EUR 73.9 million in the first quarter of 2021. The specialist in drugs for the treatment of chronic diseases and for individual therapies increased earnings disproportionately at all levels. The result from ordinary activities (EBITDA) rose by 196 % to EUR 2,823 thousand (previous year: EUR 954 thousand) and the operating result (EBIT) by 350 % to EUR 2,428 thousand. Thus, after the first three months of the current year, EBIT already exceeds the figure for 2020 as a whole. One reason for the increase in earnings is the improvement in the gross margin, which has increased from 7.2 % (previous year) to 9.8 % in the first quarter of 2021.

Rating & Research

GBC AG

Buy: 52.50 €

First Berlin Equity Research

Buy: 49.00 €

Aktienkurs

Zum Aktienchart
HAEMATO annual report 2020 mockup

Safely and well advised

Reports

Get an overview of the status and development of HAEMATO AG. Here you will find information about the group as well as the developments of the past years.

Read reports

News

We would like to inform you about the current business development of HAEMATO AG as well as about our investor relations activities.

To the news archive

Ad hoc of HAEMATO AG pursuant to Art. 17 MAR: The Supervisory Board of HAEMATO AG approved the Executive Board’s proposal for the appropriation of profits at today’s balance sheet meeting. The Executive Board and Supervisory Board will therefore propose a dividend of EUR 1.00 per dividend-bearing share at the Annual General Meeting to be […]

Corporate News of HAEMATO AG: According to the preliminary IFRS financial statements for the 2020 financial year, HAEMATO AG increased its revenue by 20.5 % to EUR 238.3 million and increased EBITDA by 74.8 % to EUR 3.3 million. In the 2020 financial year, HAEMATO AG, Schoenefeld (ISIN: DE000289VV1), achieved IFRS consolidated revenues of EUR […]

HAEMATO AG (ISIN: DE000A289VV1, WKN: A289VV) has successfully completed the capital increase which was announced on March 24, 2021. The capital increase was oversubscribed. The Company increased its share capital by € 475,391.00 to € 5,229,307.00 by issuing a total of 475,391 no-par value bearer shares against cash contributions, excluding …

Upcoming events

interim report

Interim Report 2021

Preliminary Results

Q3 Results 2021

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us